Skip to main content
SpringerLink
Log in

Colorectal Cancer

  • Chapter
Book cover Molecular Pathology in Clinical Practice

  • 3582 Accesses

Abstract

Molecular testing of colorectal cancer (CRC) has become the standard practice in the management of patients who are candidates for chemotherapy and gene- or pathway-targeted therapies, providing critical information for precision therapy. Current and emerging testing approaches and guidelines used to select EGFR pathway-targeted therapies for CRC are reviewed, as well as the use of DNA mismatch repair deficiency testing in CRC for identification of patients who might not benefit from conventional therapies containing 5-fluorouracil (5FU). Recent recommendations for extended RAS mutation testing encompassing exons 2, 3, and 4 of KRAS and NRAS in CRC are highlighted. An overview of laboratory considerations includes the critical role of tumor tissue evaluation by pathologists, in order to select the best areas of tumor for testing. In addition to a number of conventional testing platforms, given the increasing number of gene mutations that may be critical to achieve targeted therapy efficacy in CRC, advances in the use of gene panels for mutation analysis with platforms that permit detection of hundreds of mutations in a single sample, such as next-generation sequencing (NGS) gene panels, are described.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kozuch P, Malamud S, Wasserman C, Homel P, Mirzoyev T, Grossbard M. Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 2009;8(1):38–42.

    Article  CAS  PubMed  Google Scholar 

  2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.

    Article  PubMed  Google Scholar 

  3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.

    Article  CAS  PubMed  Google Scholar 

  4. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42(1):1–10.

    Article  PubMed  Google Scholar 

  5. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.

    Article  Google Scholar 

  6. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int. 2012;2012:509348.

    PubMed Central  PubMed  Google Scholar 

  7. Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruine AP, Carvalho B, Meijer GA, Schouten LJ, van den Brandt PA, Weijenberg MP, van Engeland M. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol. 2013;24(8):2048–56.

    Article  CAS  PubMed  Google Scholar 

  8. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000;97(2):710–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, French AJ, Thibodeau SN, Jass J, Haile R, Laird PW. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.

    Article  CAS  PubMed  Google Scholar 

  10. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95(12):6870–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Umar A. Lynch syndrome (HNPCC) and microsatellite instability. Dis Markers. 2004;20(4-5):179–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1–18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Alemayehu A, Sebova K, Fridrichova I. Redundant DNA methylation in colorectal cancers of Lynch-syndrome patients. Genes Chromosomes Cancer. 2008;47(10):906–14.

    Article  CAS  PubMed  Google Scholar 

  14. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Clin Cancer Res. 2008;14(21):7074–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254–61.

    Article  CAS  PubMed  Google Scholar 

  17. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.

    Article  PubMed  Google Scholar 

  18. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812–20.

    Article  PubMed  Google Scholar 

  19. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293–7.

    Article  CAS  PubMed  Google Scholar 

  20. Bokemeyer C, Kohne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, T. S. (2014). Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. ASCO 2014 Annual Meeting, Chicago, Illinois, J Clin Oncol.

    Google Scholar 

  21. Ciardiello F, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, CutsemE V. (2014). Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. ASCO 2014 Annual Meeting, Chicago, Illinois, J Clin Oncol.

    Google Scholar 

  22. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH, Kim YS. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10(1 Pt 1):191–5.

    Article  CAS  PubMed  Google Scholar 

  23. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11(1):42–65.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Grothey A. EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol. 2010;28(31):4668–70.

    Article  PubMed  Google Scholar 

  25. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.

    Article  CAS  PubMed  Google Scholar 

  26. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27(12):2091–6.

    Article  PubMed  Google Scholar 

  27. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res. 2010;16(11):2921–6.

    Article  CAS  PubMed  Google Scholar 

  28. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261–70.

    Article  PubMed  Google Scholar 

  30. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100–3.

    Article  CAS  PubMed  Google Scholar 

  31. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009;15(9):3184–8.

    Article  CAS  PubMed  Google Scholar 

  32. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69(5):1851–7.

    Article  CAS  PubMed  Google Scholar 

  33. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594–603.

    Article  PubMed  Google Scholar 

  34. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005;11(18):6650–6.

    Article  CAS  PubMed  Google Scholar 

  35. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2014;00:1–9.

    CAS  Google Scholar 

  36. Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16(9):1239–49.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, Moreno-Rubio J, Carpeno JD, Belda-Iniesta C, Barriuso J, Garcia VM, Diaz E, Burgos E, Gonzalez-Baron M, Feliu J. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy. Curr Cancer Drug Targets. 2011;12(2):124–31.

    Article  Google Scholar 

  38. Funkhouser Jr WK, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, Nowak JA. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn. 2012;14(2):91–103.

    Article  CAS  PubMed  Google Scholar 

  39. Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, Fujiwara T, Jen J, Kinzler KW, Wyllie AH, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med. 1995;1(4):348–52.

    Article  CAS  PubMed  Google Scholar 

  40. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380–7.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363(6429):558–61.

    Article  CAS  PubMed  Google Scholar 

  42. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260(5109):816–9.

    Article  CAS  PubMed  Google Scholar 

  43. Hagemann IS, Sepulveda AR. Cancer Predisposition Syndromes of the Gastrointestinal Tract. Molecular Pathology of Neoplastic Gastrointestinal Diseases. A. R. Sepulveda and J. L. Lynch, Springer, LLC, New York, NY: 109-130, (2013).

    Google Scholar 

  44. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet. 1997;17(3):271–2.

    Article  CAS  PubMed  Google Scholar 

  45. Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham JM, French AJ, Halling KC, Schwab M, Goretzki P, Thibodeau SN. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet. 1996;5(9):1245–52.

    Article  CAS  PubMed  Google Scholar 

  46. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998;95(15):8698–702.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96(15):8681–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Stone JG, Robertson D, Houlston RS. Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer. J Clin Pathol. 2001;54(6):484–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. EGAPP. Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med. 2011;13(1):67–76.

    Google Scholar 

  50. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, Redston M, Gallinger S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342(2):69–77.

    Article  CAS  PubMed  Google Scholar 

  51. Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L, Menigatti M, Roncari B, Maffei S, Rossi G, Ponti G, Santini A, Losi L, Di Gregorio C, Oliani C, Ponz de Leon M, Lanza G. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11(23):8332–40.

    Article  CAS  PubMed  Google Scholar 

  52. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27(11):1814–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767–72.

    Article  CAS  PubMed  Google Scholar 

  56. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Kerr DJ, Midgley R. Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol. 2010;28(20):3210–2.

    Article  CAS  PubMed  Google Scholar 

  58. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989;17(7):2503–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Thelwell N, Millington S, Solinas A, Booth J, Brown T. Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res. 2000;28(19):3752–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Ausch C, Buxhofer-Ausch V, Oberkanins C, Holzer B, Minai-Pour M, Jahn S, Dandachi N, Zeillinger R, Kriegshauser G. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn. 2009;11(6):508–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, Lopez-Rios F. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010;12(3):292–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, Gyuris T, Baron W, Bakker A, Parker A, Patterson SD. A comparability study of 5 commercial KRAS tests. Diagn Pathol. 2010;5:23.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Gallegos Ruiz MI, Floor K, Rijmen F, Grunberg K, Rodriguez JA, Giaccone G. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol. 2007;29(3):257–64.

    PubMed Central  CAS  PubMed  Google Scholar 

  64. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281(5375):363, 365.

    Article  PubMed  Google Scholar 

  65. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn. 2005;7(3):413–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, Iacopetta B, Soong R. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008;40(3):295–8.

    Article  CAS  PubMed  Google Scholar 

  67. Setty P, Hammes J, Rothamel T, Vladimirova V, Kramm CM, Pietsch T, Waha A. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn. 2010;12(6):750–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Sundstrom M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer. 2010;10:660.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Curry JL, Torres-Cabala CA, Tetzlaff MT, Bowman C, Prieto VG. Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. Semin Cutan Med Surg. 2012;31(4):267–73.

    Article  CAS  PubMed  Google Scholar 

  70. Bihl MP, Hoeller S, Andreozzi MC, Foerster A, Rufle A, Tornillo L, Terracciano L. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. Diagn Mol Pathol. 2012;21(1):14–23.

    Article  CAS  PubMed  Google Scholar 

  71. Cykowski MD, Allen RA, Fung KM, Harmon MA, Dunn ST. Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-neoplastic Conditions. Diagn Mol Pathol. 2012;21(4):214–20.

    Article  CAS  PubMed  Google Scholar 

  72. Lade-Keller J, Romer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, Hager H, Kristensen LS. Evaluation of BRAF mutation testing methodologies in formalin-fixed paraffin-embedded cutaneous melanomas. J Mol Diagn. 2012;15(1):70–80.

    Article  PubMed  Google Scholar 

  73. Alderborn A, Kristofferson A, Hammerling U. Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res. 2000;10(8):1249–58.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2(9):2265–75.

    Article  CAS  PubMed  Google Scholar 

  75. Lof-Ohlin ZM, Nilsson TK. Pyrosequencing assays to study promoter CpG site methylation of the O6-MGMT, hMLH1, p14ARF, p16INK4a, RASSF1A, and APC1A genes. Oncol Rep. 2009;21(3):721–9.

    PubMed  Google Scholar 

  76. Yu J, Freimuth RR, Culverhouse R, Marsh S, Watson MA, McLeod HL. DNA methylotype analysis in colorectal cancer. Oncol Rep. 2008;20(4):921–7.

    PubMed Central  CAS  PubMed  Google Scholar 

  77. Kwok CT, Ward RL, Hawkins NJ, Hitchins MP. Detection of allelic imbalance in MLH1 expression by pyrosequencing serves as a tool for the identification of germline defects in Lynch syndrome. Fam Cancer. 2010;9(3):345–56.

    Article  CAS  PubMed  Google Scholar 

  78. Chen X, Kwok PY. Template-directed dye-terminator incorporation (TDI) assay: a homogeneous DNA diagnostic method based on fluorescence resonance energy transfer. Nucleic Acids Res. 1997;25(2):347–53.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Kwok PY (2004). High-throughput genotyping with primer extension fluorescent polarization detection. Current protocols in human genetics/editorial board, Jonathan L. Haines … [et al.] Chapter 2: Unit 2 11.

    Google Scholar 

  80. Magnin S, Viel E, Baraquin A, Valmary-Degano S, Kantelip B, Pretet JL, Mougin C, Bigand M, Girardo B, Borg C, Ferrand C. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J Mol Diagn. 2011;13(5):485–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  81. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One. 2012;7(4), e35309.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Jurinke C, Oeth P, van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol Biotechnol. 2004;26(2):147–64.

    Article  CAS  PubMed  Google Scholar 

  83. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011;13(1):64–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Sequenom (2012). Sequenom MassARRAY®System for Somatic Mutation Screening. Doc. No. WKI 35-175, R1.0, CO No. 100004. 2012, from http://www.sequenom.com.

  85. Laosinchai-Wolf W, Ye F, Tran V, Yang Z, White R, Bloom K, Choppa P, Labourier E. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens. J Clin Pathol. 2011;64(1):30–6.

    Article  CAS  PubMed  Google Scholar 

  86. Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologist’s role in the era of personalized medicine. Adv Anat Pathol. 2010;17(1):23–32.

    CAS  PubMed  Google Scholar 

  87. Labourier E. Do pre-analytical parameters explain KRAS test sensitivity disparities? J Mol Diagn. 2012;14(6):631–3. author reply 632-633.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

    Antonia R. Sepulveda M.D., Ph.D.

  2. Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

    Deqin Ma M.D., Ph.D.

  3. Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, USA

    Kathryn C. Behling M.D., Ph.D.

  4. Department of Pathology, Cooper University Hospital, Camden, NJ, USA

    Kathryn C. Behling M.D., Ph.D.

  5. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA

    Helen Fernandes Ph.D.

Authors
  1. Antonia R. Sepulveda M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deqin Ma M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathryn C. Behling M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Helen Fernandes Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonia R. Sepulveda M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, University of Vermont College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA

    Debra G.B. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sepulveda, A.R., Ma, D., Behling, K.C., Fernandes, H. (2016). Colorectal Cancer. In: Leonard, D. (eds) Molecular Pathology in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-19674-9_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19674-9_31

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19673-2

  • Online ISBN: 978-3-319-19674-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation